1. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma
- Author
-
Meyer, Ralph M., Quirt, Ian C., Skillings, Jamey R., Cripps, M.C., Bramwell, Vivien H.C., Weinerman, Brian H., Gospodarowicz, Mary K., Burns, Bruce F., Sargeant, Ann Marie, Shepherd, Lois E., Zee, Benny, and Hryniuk, William M.
- Subjects
Non-Hodgkin's lymphomas ,Doxorubicin -- Dosage and administration ,Chemotherapy -- Evaluation - Abstract
Increased doses of doxorubicin may not improve the survival of non-Hodgkin's lymphoma patients. Non-Hodgkin's lymphoma is a cancer of the lymph tissue accompanied by lymph node enlargement. Of 238 patients with non-Hodgkin's lymphoma, 119 were assigned to receive increased doses of doxorubicin and 119 were assigned to receive standard doses. Because of severe white blood cell depletion, only 56 patients received escalated doses. The two groups did not differ in their response to treatment. The overall response rate was 88% in the escalated therapy group and 84% in the standard therapy group. Forty-eight percent of those in the escalated therapy group survived five years, compared to 60% in the standard therapy group. The five-year survival rates without disease progression were 51% in the escalated therapy group and 53% in the standard therapy group. More deaths in the escalated therapygroup were a result of treatment complications or drug toxicity than in the standard therapy group.
- Published
- 1993